Freeline Therapeutics Holdings plc (FRLN)

$0.7695

+0.05 (+6.77%)
Rating:
Recommendation:
-
Symbol FRLN
Price $0.7695
Beta -0.046
Volume Avg. 0.08M
Market Cap 49.996M
Shares () -
52 Week Range 0.65-3.91
1y Target Est -
DCF Unlevered FRLN DCF ->
DCF Levered FRLN LDCF ->
ROE -73.56% Strong Sell
ROA -60.24% Strong Sell
Operating Margin -
Debt / Equity 65.46% Buy
P/E -
P/B 0.28 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest FRLN news


Ms. Theresa Marie Heggie
Healthcare
Biotechnology
NASDAQ Global Select

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.